Patent · US Active

Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods

US9783586B2 · kind B2 · utility

0Cited by

1References

40Claims

0Family size

Assignee

The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

Louis M. Staudt · Silver Spring, US
Yibin Yang · San Jose, US
Federico Bernal · Brookline, US
Amanda L. Whiting · Frederick, US

Key dates

Filing date	Mar 11, 2014
Grant date	Oct 10, 2017
Priority date	—
Expiry date	Mar 11, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/57407
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphoma (ABC DLBCL) and autoimmune or inflammatory disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.